480 related articles for article (PubMed ID: 26524087)
1. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
2. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
[TBL] [Abstract][Full Text] [Related]
3. Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer.
Ilg AM; Laviana AA; Kamrava M; Veruttipong D; Steinberg M; Park SJ; Burke MA; Niedzwiecki D; Kupelian PA; Saigal C
Brachytherapy; 2016; 15(6):760-767. PubMed ID: 27720202
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison.
Eldefrawy A; Katkoori D; Abramowitz M; Soloway MS; Manoharan M
Urol Oncol; 2013 Jul; 31(5):576-80. PubMed ID: 21616691
[TBL] [Abstract][Full Text] [Related]
5. Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing.
Ning MS; Klopp AH; Jhingran A; Lin LL; Eifel PJ; Vedam S; Lawyer AA; Olivieri ND; Guzman AB; Incalcaterra JR; Mesko SM; Pezzi TA; Boyce-Fappiano DR; Shaitelman SF; Frank SJ; Thaker NG
Brachytherapy; 2019; 18(4):445-452. PubMed ID: 30992185
[TBL] [Abstract][Full Text] [Related]
6. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.
Shah C; Lanni TB; Ghilezan MI; Gustafson GS; Marvin KS; Ye H; Vicini FA; Martinez AA
Brachytherapy; 2012; 11(6):441-5. PubMed ID: 22728157
[TBL] [Abstract][Full Text] [Related]
7. Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
Schroeck FR; Jacobs BL; Bhayani SB; Nguyen PL; Penson D; Hu J
Eur Urol; 2017 Nov; 72(5):712-735. PubMed ID: 28366513
[TBL] [Abstract][Full Text] [Related]
8. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
Nguyen PL; Gu X; Lipsitz SR; Choueiri TK; Choi WW; Lei Y; Hoffman KE; Hu JC
J Clin Oncol; 2011 Apr; 29(12):1517-24. PubMed ID: 21402604
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
[TBL] [Abstract][Full Text] [Related]
10. A Multidimensional Analysis of Prostate Surgery Costs in the United States: Robotic-Assisted versus Retropubic Radical Prostatectomy.
Bijlani A; Hebert AE; Davitian M; May H; Speers M; Leung R; Mohamed NE; Sacks HS; Tewari A
Value Health; 2016 Jun; 19(4):391-403. PubMed ID: 27325331
[TBL] [Abstract][Full Text] [Related]
11. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
12. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
[TBL] [Abstract][Full Text] [Related]
13. An economic analysis of conservative management versus active treatment for men with localized prostate cancer.
Perlroth DJ; Bhattacharya J; Goldman DP; Garber AM
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):250-7. PubMed ID: 23271781
[TBL] [Abstract][Full Text] [Related]
14. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies.
Muralidhar V; Nguyen PL
Urol Oncol; 2017 Feb; 35(2):76-85. PubMed ID: 27473636
[TBL] [Abstract][Full Text] [Related]
15. Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial.
Forsmark A; Gehrman J; Angenete E; Bjartell A; Björholt I; Carlsson S; Hugosson J; Marlow T; Stinesen-Kollberg K; Stranne J; Wallerstedt A; Wiklund P; Wilderäng U; Haglind E
Eur Urol; 2018 Dec; 74(6):816-824. PubMed ID: 30143383
[TBL] [Abstract][Full Text] [Related]
16. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.
Shaverdian N; Verruttipong D; Wang PC; Kishan AU; Demanes DJ; McCloskey S; Kupelian P; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):516-525. PubMed ID: 28126301
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
19. Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer.
Bolenz C; Gupta A; Hotze T; Ho R; Cadeddu JA; Roehrborn CG; Lotan Y
Eur Urol; 2010 Mar; 57(3):453-8. PubMed ID: 19931979
[TBL] [Abstract][Full Text] [Related]
20. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]